Cargando…
Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for pr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690387/ https://www.ncbi.nlm.nih.gov/pubmed/33105647 http://dx.doi.org/10.3390/jcm9113388 |
_version_ | 1783614056183103488 |
---|---|
author | Utsunomiya, Akira Oyama, Noritaka Hasegawa, Minoru |
author_facet | Utsunomiya, Akira Oyama, Noritaka Hasegawa, Minoru |
author_sort | Utsunomiya, Akira |
collection | PubMed |
description | Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for precise diagnosis, prediction of clinical course, and evaluation of the therapeutic responsiveness of disease are required in clinical practice. SSc-specific autoantibodies are currently used for diagnosis and prediction of clinical features, as other biomarkers have not yet been fully vetted. Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and CCL18 have been considered as serum biomarkers of SSc-related interstitial lung disease. Moreover, levels of circulating brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) can provide diagnostic information and indicate the severity of pulmonary arterial hypertension. Assessment of several serum/plasma cytokines, chemokines, growth factors, adhesion molecules, and other molecules may also reflect the activity or progression of fibrosis and vascular involvement in affected organs. Recently, microRNAs have also been implicated as possible circulating indicators of SSc. In this review, we focus on several potential SSc biomarkers and discuss their clinical utility. |
format | Online Article Text |
id | pubmed-7690387 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76903872020-11-27 Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update Utsunomiya, Akira Oyama, Noritaka Hasegawa, Minoru J Clin Med Review Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by dysregulation of the immune system, vascular damage, and fibrosis of the skin and internal organs. Patients with SSc show a heterogeneous phenotype and a range of clinical courses. Therefore, biomarkers that are helpful for precise diagnosis, prediction of clinical course, and evaluation of the therapeutic responsiveness of disease are required in clinical practice. SSc-specific autoantibodies are currently used for diagnosis and prediction of clinical features, as other biomarkers have not yet been fully vetted. Krebs von den Lungen-6 (KL-6), surfactant protein-D (SP-D), and CCL18 have been considered as serum biomarkers of SSc-related interstitial lung disease. Moreover, levels of circulating brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) can provide diagnostic information and indicate the severity of pulmonary arterial hypertension. Assessment of several serum/plasma cytokines, chemokines, growth factors, adhesion molecules, and other molecules may also reflect the activity or progression of fibrosis and vascular involvement in affected organs. Recently, microRNAs have also been implicated as possible circulating indicators of SSc. In this review, we focus on several potential SSc biomarkers and discuss their clinical utility. MDPI 2020-10-22 /pmc/articles/PMC7690387/ /pubmed/33105647 http://dx.doi.org/10.3390/jcm9113388 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Utsunomiya, Akira Oyama, Noritaka Hasegawa, Minoru Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title | Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title_full | Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title_fullStr | Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title_full_unstemmed | Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title_short | Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update |
title_sort | potential biomarkers in systemic sclerosis: a literature review and update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690387/ https://www.ncbi.nlm.nih.gov/pubmed/33105647 http://dx.doi.org/10.3390/jcm9113388 |
work_keys_str_mv | AT utsunomiyaakira potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate AT oyamanoritaka potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate AT hasegawaminoru potentialbiomarkersinsystemicsclerosisaliteraturereviewandupdate |